pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Alecensa
drug
save

alectinib

Marketedupdated 6mo ago
by F. Hoffmann-La Roche Ltd
Approved
community read0 votes

indications

investigational
NSCLC

all catalysts(0)

nothing on the calendar yet

Trials studying alectinib

  • phase2A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)active not recruitingn=99
  • phase2Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Gliomanot yet recruitingn=50
  • phase3Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphismsactive not recruitingn=600
  • —Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapyrecruitingn=800
  • phase3Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCrecruitingn=450
  • phase2Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Studyactive not recruitingn=920
  • phase3A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Studyactive not recruitingn=1,000
  • phase2A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumorsrecruitingn=42

Patent cliff

source: FDA Orange Book
first barrier falls
Apr 18, 2027
150 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (5)

  • Apr 24, 2035formulationUS 10350214
  • Apr 24, 2035formulationUS 11433076
  • Mar 4, 2032formulationUS 9365514
  • May 29, 2031compositionUS 91269314.5y
  • Jun 9, 2030formulationUS 94409223.6y

FDA exclusivities (2)

  • Apr 18, 2031ODE-477Orphan Drug (7y)4.4y
  • Apr 18, 2027I-947Indication (3y)150d

News(2)

  • FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
    The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
    biopharma_dive · 7h ago
  • GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
    Nelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.
    biospace · 8h ago
brand
Alecensa
generic
alectinib
indication
Non-Small Cell Lung Cancer
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 59m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?